# Kindred Biosciences, Inc.

Kindred Biosciences, Inc. is a company headquartered in Burlingame, CA, United States.

## Company overview

- **Legal name:** Kindred Biosciences, Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Burlingame, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001561743

## About

Kindred Biosciences, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001561743, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2021-03-16, it reported annual revenue of USD 42,164,000; net income of USD -21,796,000; total assets of USD 95,814,000 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $42.2M (USD 42,164,000)
- **Net income:** -$21.8M (USD -21,796,000)
- **Total assets:** $95.8M (USD 95,814,000)
- **Cash and equivalents:** $11.6M (USD 11,620,000)
- **Operating cash flow:** -$9.9M (USD -9,857,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $4.3M (USD 4,256,000)
- **Net income:** -$61.4M (USD -61,389,000)
- **Total assets:** $114.0M (USD 114,024,000)
- **Cash and equivalents:** $16.0M (USD 15,986,000)
- **Operating cash flow:** -$56.3M (USD -56,342,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $2.0M (USD 1,966,000)
- **Net income:** -$49.7M (USD -49,690,000)
- **Total assets:** $106.5M (USD 106,482,000)
- **Cash and equivalents:** $56.3M (USD 56,302,000)
- **Operating cash flow:** -$45.0M (USD -45,035,000)

### FY2017 (period ended 2017-12-31)

- **Net income:** -$30.9M (USD -30,879,000)
- **Total assets:** $90.8M (USD 90,822,000)
- **Cash and equivalents:** $34.8M (USD 34,813,000)
- **Operating cash flow:** -$21.9M (USD -21,878,000)

## Recent SEC filings

- Form 8-K — filed 2021-08-30 — period 2021-08-27 — 8-K
- Form 8-K — filed 2021-08-26 — period 2021-08-25 — 8-K
- Form 10-Q — filed 2021-08-05 — period 2021-06-30 — 10-Q
- Form SC 13D — filed 2021-08-03
- Form 8-K — filed 2021-08-02 — period 2021-07-30 — 8-K
- Form 8-K — filed 2021-07-01 — period 2021-06-30 — 8-K
- Form SC 13D — filed 2021-06-25 — SC 13D
- Form SC 13D — filed 2021-06-25 — SC 13D
- Form SC 13G — filed 2021-06-24
- Form 8-K — filed 2021-06-24 — period 2021-06-22 — 8-K
- Form 8-K — filed 2021-06-16 — period 2021-06-15 — 8-K
- Form 8-K — filed 2021-06-02 — period 2021-06-02 — 8-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/kindred-biosciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology